What Moderna's 8-K filings say: 5 filings, latest Sep 30, 2026
Moderna filed its latest 8-K with the SEC on Sep 30, 2026. It discusses capex increase, COO change and restructuring.
Public (MRNA)Biotechnology Research5,001 to 10,000 employeesmodernatx.comLinkedIn
Get Moderna's live signals in Claude or ChatGPT, or by API
What changed at Moderna this week? Use Autobound signals for modernatx.com.- Filed
- Sep 30, 2026
- Filings
- 5
- Signals
- 12
Source: Autobound Signal API · 106 signals tracked for Moderna · updated
8-K · latest 6
What Moderna's 8-K filings say
- SEC EDGAR
8-K
Filed · 3 signals
The creation of a new COO position, filled by an executive who previously led the company's massive manufacturing scale-up, signals a strategic focus on expanding operations.
$5M
New hire equity award for incoming COO
90%
Annual cash bonus target as a percentage of base salary for new COO
The creation of a new COO role, filled by an executive known for scaling manufacturing, indicates significant upcoming investment in operations, supply chain, and production capacity.
- SEC EDGAR
8-K
Filed · 3 signals
Moderna raises $3 billion in capital via convertible senior notes offering
Moderna has secured $3 billion in fresh capital, signaling major investments are likely planned for R&D, clinical trials, manufacturing scale-up, or potential acquisitions.
$3B
Aggregate principal amount of convertible senior notes offering
U.S. Bank Trust Company, National Association
- SEC EDGAR
8-K
Filed · 3 signals
The appointment of a new board member with extensive public company financial leadership experience, along with a shuffle in Audit Committee members, signals a potential shift in financial oversight and governance strategy.
IQVIA Holdings Inc.Biogen Inc.
- SEC EDGAR
8-K
Filed · 2 signals
Moderna receives FDA Refusal-to-File letter for influenza vaccine mRNA-1010
The FDA's refusal to review the biologics license application (BLA) for the mRNA-1010 vaccine is a major regulatory and quality setback.
- SEC EDGAR
8-K
Filed · 1 signal
Moderna projects significant FY2025 operating loss with $5.0-5.2B in expenses against $1.9B revenue.
The company anticipates operating expenses will be more than double its annual revenue, resulting in a substantial operating loss exceeding $3 billion.
$5.1B
midpoint of projected GAAP operating expenses for FY2025
Showing 6 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Moderna with the Signal API
One POST /v1/companies/enrich call with modernatx.com returns Moderna 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"modernatx.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about Moderna 8-K
When did Moderna file its latest 8-K?
What did Moderna disclose in its latest 8-K?
Where can I read Moderna's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .